ReviewRSC medicinal chemistry2026
Recent advances in the development of acridine-based hybrids with antiproliferative activity.
Review in RSC medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer remains a leading cause of mortality worldwide, with the limitations of conventional single-target therapies, such as severe side effects and drug resistance, driving the need for innovative treatment strategies. Molecular hybridization has emerged as a powerful rational drug design approach to develop multi-target agents capable of simultaneously modulating various oncogenic pathways. Among the diverse scaffolds explored, the acridine core, a tricyclic, planar heteroaromatic structure, stands out due to its inherent DNA-intercalating ability and potent antiproliferative activity through mechanisms like topoisomerase inhibition. This review provides a comprehensive overview of recent advances (2019-2025) in the design, synthesis, evaluation, and perspectives of acridine-based hybrids as antiproliferative agents. It systematically surveys a vast array of hybrids, classifying them by their dominant secondary pharmacophores to offer a structured and practical overview of the field. Particular attention is given to structure-activity relationships (SARs), illustrating how strategic modifications can affect cytotoxicity, selectivity, and underlying mechanistic pathways. The biological evaluation of these hybrids encompasses a range of
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.